Halcinonide
- Atc Codes:D07AD02
- CAS Codes:3093-35-4
- PHARMGKB ID:3093-35-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Czech Republic: Betacorton; Estonia: Betacorton; Ireland: Halciderm; Italy: Halciderm; Latvia: Betacorton; Lithuania: Betacorton; Slovakia: Betacorton.
North America
Canada: Halog; USA: Halog.
Latin America
Brazil: Halog; Mexico: Dermalog.
Asia
Japan: Adcortin, Mutayain, Sawastin.
Drug combinations
Halcinonide, Neomycin, and Nystatin
Chemistry
Halcinonide: C~24~H~32~ClFO~5~. Mw: 454.96. (1) Pregn-4-ene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α)-; (2) 21-Chloro-9-fluoro-11β,16α,17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. CAS-3093-35-4 (1973).
Pharmacologic Category
Skin and Mucous Membrane Agents; Anti-inflammatory. Topical Corticosteroid. (ATC-Code: D07AD02).
Mechanism of action
Halcinonide, a synthetic fluorinated corticosteroid, decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.
Therapeutic use
Halcinonide shares actions of the other topical corticosteroids and is used for relief of inflammatory manifestations of corticosteroid-responsive dermatoses.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to halcinonide or any component of the formulation. Viral, fungal, or tubercular skin lesions.
Warnings and precautions
Systemic absorption of topical corticosteroids may cause HPA axis suppression (reversible) particularly in younger children. Allergic contact dermatitis can occur. Prolonged treatment with corticosteroids associated with development of Kaposi’s sarcoma (case reports). Adverse systemic effects including hyperglycemia, glycosuria, fluid and electrolyte changes, and HPA suppression may occur when used on large surface areas, for prolonged periods, or with occlusive dressing. Chronic use of corticosteroids in children may interfere with growth and development. For external use only.